Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 1—January 2004

Dispatch

Antifungal Susceptibilities of Cryptococcus neoformans

Lennox K. Archibald*1Comments to Author , Marion J. Tuohy†, Deborah A. Wilson†, Okey Nwanyanwu‡, Peter N. Kazembe‡, Somsit Tansuphasawadikul§, Boonchuay Eampokalap§, Achara Chaovavanich§, L.Barth Reller¶, William R. Jarvis*, Gerri S. Hall†, and Gary W. Procop†
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Cleveland Clinic Foundation, Cleveland, Ohio, USA; ‡Lilongwe Central Hospital, Lilongwe, Malawi; §Bamrasnaradura Hospital, Nonthaburi, Thailand; ¶Duke University Medical Center, Durham, North Carolina, USA

Main Article

Table 1

Cryptococcus neoformans susceptibility results

Antifungal agent MIC range (μg/mL) MIC50 (μg/mL) MIC90 (μg/mL) MIC geometric mean (μg/mL)
U.S. isolates (N = 20)
   Amphotericin B 1–2 1 2 1.4
   Fluconazole 1–16 8 8 5.1
   Itraconazole 0.016–0.125 0.06 0.125 0.06
   5-Flucytosine 2–8 4 8 5.1
   Ketoconazole <0.008–0.250 0.06 0.06 0.05
Thailand isolates (N = 29)
   Amphotericin B 0.5–2 1 2 1.2
   Fluconazole 4–160 8 16 7.7
   Itraconazole 0.030–0.125 0.06 0.06 0.06
   5-Flucytosine 2–8 4 8 4.6
   Ketoconazole 0.030–0.250 0.06 0.125 0.07
Malawi isolates (N = 16)
   Amphotericin B 1–2 2 2 1.6
   Fluconazole 4–32 8 16 7.6
   Itraconazole 0.030–0.125 0.03 0.125 0.05
   5-Flucytosine 1–16 4 8 4.5
   Ketoconazole 0.016–0.250 0.03 0.25 0.03

Main Article

1 Present address: Regeneration Technologies, Inc., Alachua, Florida, USA.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO